Successful Treatment of Previously Uncontrolled Adult Asthma with Budesonide Inhalation Suspension: Five-Year Case Histories

医学 哮喘 布地奈德 吸入器 剂量 吸入 皮质类固醇 干粉吸入器 雾化器 病历 麻醉 儿科 重症监护医学 内科学
作者
Sandra M. Gawchik
出处
期刊:Annals of Pharmacotherapy [SAGE Publishing]
卷期号:41 (10): 1728-1733 被引量:6
标识
DOI:10.1345/aph.1k133
摘要

To determine whether nebulized budesonide inhalation suspension (BIS) is effective in treating adults with asthma that has been uncontrolled by inhaled therapies.Three adults with severe persistent asthma were switched to BIS after poor outcomes with other controller medications, including inhaled corticosteroids (ICSs). BIS dosages were initiated with 1 mg twice daily. Based on physician discretion as symptoms improved, dosages were decreased to 0.5 mg twice daily (2 pts.) or once daily (1 pt.). Patients were instructed to self-manage their asthma, increasing their dosages during periods of asthma worsening. Peak expiratory flow (PEF) was assessed before and after the initiation of BIS. The number of healthcare visits and oral corticosteroid courses recorded in patient medical records during the 3 years before and 5 years after initiation of BIS therapy were compared. In all 3 cases, BIS improved asthma control. BIS consistently increased PEF and reduced the number of urgent care visits and oral corticosteroid courses. All patients reported satisfaction with BIS therapy.Despite proven effectiveness of ICSs for persistent asthma, some patients fail to respond optimally to treatment administered via an inhaler. These 3 case reports suggest that BIS is effective in treating adults with severe persistent asthma who fail to respond optimally to treatment with other ICS preparations. Failure to use inhalers properly, previous poor adherence in 1 case, or patient preference for the nebulizer might explain why nebulized BIS was more effective than other inhaler therapies.Switching adults with uncontrolled asthma to BIS therapy may be a valuable treatment option for those who are unable to achieve optimal asthma control, despite asthma education and training on inhaler technique.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
navy900完成签到,获得积分10
刚刚
DijiaXu应助萝卜采纳,获得10
1秒前
星辰大海应助ddffgz采纳,获得10
1秒前
LY发布了新的文献求助10
1秒前
FashionBoy应助逆时针采纳,获得10
1秒前
上官若男应助淘气科研采纳,获得10
1秒前
2秒前
AI_S发布了新的文献求助10
3秒前
天天快乐应助专注涵雁采纳,获得10
3秒前
ztt发布了新的文献求助10
3秒前
Muya发布了新的文献求助10
3秒前
NexusExplorer应助碧蓝的弱采纳,获得10
3秒前
Fine完成签到,获得积分10
3秒前
洺全发布了新的文献求助10
3秒前
情怀应助姜锦令采纳,获得10
4秒前
Jasper应助GSX采纳,获得10
5秒前
pp完成签到 ,获得积分10
5秒前
6秒前
李爱国应助小玉采纳,获得10
6秒前
我是站长才怪给冥冥之极为昭昭的求助进行了留言
6秒前
6秒前
热心书易完成签到,获得积分10
6秒前
完美怀蕾完成签到,获得积分10
7秒前
啦啦啦啦发布了新的文献求助10
7秒前
丹儿完成签到,获得积分10
8秒前
KerryDoe完成签到,获得积分10
9秒前
pluto应助哈哈哈哈采纳,获得10
9秒前
10秒前
丹儿发布了新的文献求助10
11秒前
Ccc发布了新的文献求助10
12秒前
shiizii应助lalaland采纳,获得10
12秒前
无私的芹应助fcc采纳,获得10
13秒前
从若完成签到,获得积分10
13秒前
搜集达人应助橘橙色采纳,获得10
13秒前
14秒前
三物完成签到 ,获得积分10
14秒前
火柴完成签到,获得积分10
14秒前
15秒前
Hui完成签到,获得积分10
16秒前
16秒前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
徐淮辽南地区新元古代叠层石及生物地层 2000
A new approach to the extrapolation of accelerated life test data 1000
Global Eyelash Assessment scale (GEA) 500
Robot-supported joining of reinforcement textiles with one-sided sewing heads 400
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4025388
求助须知:如何正确求助?哪些是违规求助? 3565158
关于积分的说明 11348564
捐赠科研通 3296332
什么是DOI,文献DOI怎么找? 1815609
邀请新用户注册赠送积分活动 890172
科研通“疑难数据库(出版商)”最低求助积分说明 813320